Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials

Cancer Journal

Volumn 15, Issue 5, 2009, Pages 421-425

  Buyse, Marc ^a,b  

^a INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

^b HASSELT UNIVERSITY   (Belgium)

Author keywords

Biomarker; Breast cancer; Colorectal cancer; Meta analysis; Ovarian cancer; Prostate cancer; Surrogate endpoint

Indexed keywords

BIOLOGICAL MARKER;

BREAST TUMOR; CANCER GROWTH; CANCER RESEARCH; CANCER RISK; CANCER SURVIVAL; COLON TUMOR; DISEASE MARKER; HUMAN; META ANALYSIS; OVARY TUMOR; PRIORITY JOURNAL; PROSTATE TUMOR; REVIEW; VALIDATION STUDY;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; META-ANALYSIS AS TOPIC; NEOPLASMS; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 70350156608     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3181b9c602     Document Type: Review

References (45)

1. DiLeo A, Bleiberg H, Buyse M. Overall survival is not a realistic endpoint for clinical trials in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer. J Clin Oncol. 2003;21:2045-2047.
2. DiLeo A, Bleiberg H, Buyse M. Is overall survival a realistic primary endpoint in advanced colorectal cancer? A critical assessment based on four clinical trials comparing fluorouracil plus leucovorin with the same treatment combined either with oxaliplatin or with irinotecan. Ann Oncol. 2004;15:545-549.
3. Sargent DJ, Hayes DF. Assessing the measure of a new drug: is survival the only thing that matters? J Clin Oncol. 2008;26:1922-1923.
4. Schilsky RL. Endpoints in cancer clinical trials and the drug approval process. Clin Cancer Res. 2002;8:935-938.
5. Stewart DJ, Kurzrock R. Cancer: the road to Amiens. J Clin Oncol. 2009; 27:328-333.
6. Biomarker Definition Working Group. (2001). Biomarkers and surrogate end-points: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89-95.
7. Temple RJ. A regulatory authority's opinion about surrogate endpoints. In: Nimmo WS, Tucker GT, eds. Clinical Measurement in Drug Evaluation. New York: Wiley; 1995:3-22.
8. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version1.1). Eur J Cancer. 2009;45:228-247.
9. Dancey JE, Dodd LE, Ford R, et al. Recommendations for the assessment of progression in randomized cancer treatment trials. Eur J Cancer. 2009;45: 281-289.
10. Lesko LJS, Atkinson AJ. Use of biomarkers and surrogate end-points in drug development and regulatory decision making: criteria, validation, strategies. Ann Rev Pharmacol Toxicol. 2001;41;347-366.
11. Sridhara R, Eisenberger MA, Sinibaldi VJ, et al. Evaluation of prostatespecific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. J Clin Oncol. 1995;13:2944-2953.
12. Smith DC, Dunn RL, Stawderman MS, et al. Change in serum prostatespecific antigen as a marker of response to cytotoxic therapy for hormonerefractory prostate cancer. J Clin Oncol. 1998;16:1835-1843.
13. Buyse M, Thirion P, Carlson RW, et al, for the Meta-Analysis Group In Cancer. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Lancet. 2000;356: 373-378.
14. Burzykowski T, Molenberghs G, Buyse M, et al. The validation of surrogate endpoints using data from randomized clinical trials: a case-study in advanced colorectal cancer. J Roy Stat Soc A. 2004;167:103-124.
15. Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate endpoints in metastatic breast cancer. J Clin Oncol. 2008;26:1987-1992.
16. Prentice RL. Surrogate endpoints in clinical trials: definitions and operational criteria. Stat Med. 1989;8:431-440.
17. Schatzkin A, Freedman LS, Schiffman MH, et al. Validation of intermediate end points in cancer research. J Natl Cancer Inst. 1990;82:1746-1752.
18. Freedman LS, Graubard BI, Schatzkin A. Statistical validation of intermediate endpoints for chronic diseases. Stat Med. 1992;11:167-178.
19. Buyse M, Molenberghs G. Criteria for the validation of surrogate end-points in randomized experiments. Biometrics. 1998;54:1014-1029.
20. Buyse M, Molenberghs G, Burzykowski T, et al. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics. 2000; 1:49-68.
21. Lassere M, Johnson K, Boers M, et al. Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. J Rheumatol. 2007;34:607-615.
22. Weir CJ, Walley RJ. Statistical evaluation of biomarkers as surrogate endpoints: a literature review. Stat Med. 2006;25:183-203.
23. Molenberghs G, Buyse M, Geys H, et al. Statistical challenges in the evaluation of surrogate endpoints in randomized trials. Control Clin Trials. 2002;23:607-625.
24. Sargent D, Wieand S, Haller DG, et al. Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2005;23:8664-8670.
25. Burzykowski T, Buyse M, Sargent D, et al. Exploring and validating surrogate endpoints in colorectal cancer. Lifetime Data Anal. 2008;14:54-64.
26. Michiels S, Le Maître A, Buyse M, et al. Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data. Lancet Oncol. 2009;10:341-350.
27. Burzykowski T, Molenberghs G, Buyse M, et al. Validation of surrogate endpoints in multiple randomized clinical trials with failure-time endpoints. J Roy Stat Soc C Appl Stat. 2001;50:405-422.
28. Buyse M, Burzykowski T, Carroll K, et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol. 2007;25: 5218-5224.
29. Buyse M, Vangeneugden T, Bijnens L, et al. Validation of biomarkers as surrogates for clinical endpoints. In: Bloom JC, Dean RA, eds. Biomarkers in Clinical Drug Development. New York: Marcel Dekker; 2003:149-168.
30. Collette L, Burzykowski T, Carroll KJ, et al. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? J Clin Oncol. 2005;23:6139-6148.
31. Molenberghs G, Burzykowski T, Alonso A, et al. The meta-analytic framework for the evaluation of surrogate endpoints in clinical trials. J Stat Plan Infer. 2008;138:432-449.
32. Burzykowski T, Molenberghs G, Buyse M, eds. The Evaluation of Surrogate Endpoints. New York: Springer; 2005.
33. Buyse M, Burzykowski T, Michiels S, et al. Individual- and trial-level surrogacy in colorectal cancer. Stat Methods Med Res. 2008;17:5.
34. Alonso A, Molenberghs G, Geys H, et al. A unifying approach for surrogate marker validation based on Prentice's criteria. Stat Med. 2006;25:205-221.
35. Alonso A, Molenberghs G. Surrogate marker evaluation from an information theory perspective. Biometrics. 2006;63;180-186.
36. Buyse M, Piedbois P, Piedbois Y, et al. Meta-analysis: methods, strengths and weaknesses. Oncology. 2000;14:437-443.
37. Buyse M. Contributions of meta-analyses based on individual patient data to therapeutic progress in colorectal cancer. Int J Clin Oncol. 2009;14:95-101.
38. Buyse M, Piedbois P. Meta-analyses, use and misuse. J Clin Oncol. 1993; 11:382.
39. Piedbois P, Buyse M. Meta-analyses need time, collaboration and funding. J Clin Oncol. 1994;12:878-879.
40. Buyse M, Carlson RW, Piedbois P. Meta-analyses of published results are unreliable. J Clin Oncol. 1999;16:1646-1647.
41. Piedbois P, Buyse M. Meta-analyses based on abstracted data: a step in the right direction, but only a first step. J Clin Oncol. 2004;22:3839-3841.
42. Burzykowski T, Buyse M. Surrogate threshold effect: An alternative measure for meta-analytic surrogate endpoint validation. Pharm Stat. 2006;5:173-186.
43. Petrylak DP, Ankerst DP, Jiang CS, et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst. 2006;98:516-521.
44. Armstrong AJ, Garrett-Mayer E, Ou Yang YC, et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol. 2007;25:3965-3970.
45. Collette L, Buyse M, Burzykowski T. Are prostate-specific antigen changes valid surrogates for survival in hormone-refractory prostate cancer? A metaanalysis is needed! J Clin Oncol. 2007;25:5673-5674.